Retatrutide TRIUMPH-4: weight loss meets osteoarthritis pain relief

Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-4 trial on 11 December 2025, showing its triple-agonist retatrutide delivered a mean weight loss of 26.5% alongside significant improvement in knee osteoarthritis (OA) pain. The trial is the first successful Phase 3 obesity study to demonstrate concurrent osteoarthritis pain reduction as a key secondary endpoint.

Key findings

  • Mean weight loss: 26.5% at the primary endpoint, consistent with retatrutide's profile across the TRIUMPH programme.
  • Knee OA pain: Statistically significant improvement in knee osteoarthritis pain scores compared to placebo, as measured by validated pain assessment instruments.
  • Safety: The adverse event profile was consistent with prior retatrutide trials, with gastrointestinal effects (nausea, diarrhoea, vomiting) being the most commonly reported.

Significance for peptide research

Retatrutide is a triple GIP, GLP-1, and glucagon receptor agonist — the most pharmacologically complex of the incretin-based obesity peptides to reach late-stage trials. The TRIUMPH-4 results are notable because they extend retatrutide's therapeutic potential beyond weight loss alone, demonstrating disease-modifying effects on osteoarthritis, a condition strongly associated with obesity-related mechanical and inflammatory stress.

The osteoarthritis benefit likely reflects both mechanical unloading (from weight reduction) and potential direct anti-inflammatory effects mediated through glucagon receptor agonism, though further mechanistic studies are needed to delineate these contributions.

TRIUMPH programme context

TRIUMPH-4 is part of a broader Phase 3 programme that includes TRIUMPH-1 (pivotal obesity trial, which demonstrated up to 30.3% weight loss at 104 weeks) and additional studies examining metabolic and cardiovascular outcomes. The consistency of weight loss across trials — ranging from 26.5% to over 30% — positions retatrutide among the most efficacious anti-obesity peptides in clinical development.

UK relevance

Retatrutide is not yet licensed in the UK. If approved, it would face NICE health technology appraisal, where its osteoarthritis benefit could strengthen its value proposition relative to existing GLP-1 and dual-agonist therapies. Researchers should note that the MHRA would require a separate marketing authorisation application.

What this means for researchers

These results reinforce the therapeutic potential of triple-agonist peptide design. For research purposes, retatrutide remains an investigational compound — it is not approved for human use in any jurisdiction as of the trial readout. The data contribute to the growing evidence base supporting multi-receptor agonism as a strategy for metabolic disease.

— This article is for research and educational purposes only. Retatrutide is an investigational compound not licensed for human use in the UK.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.